Kornimate/medical-research-clean huggingface dataset:
cancer survivorship in hematologic malignancies

Conditions: Cancer Survivors

Summary: general objective: to improve care for haematological cancer survivors. this study will (i) estimate the incidence of cancer survivor syndrome (css) in adult egyptian patients with haematological neoplasms (hn). (ii) asses the risk factors of css in patients with hn. (iii) study the effect of css on quality of life in patients with hn. (iv) to explore coping strategies of patients with hn having css

according to the american cancer society the term cancer survivor refersto people who have no signs of cancer after finishing treatment, people receiving extended treatment over a longer period of time to control the cancer or reduce risk of its return, and people with advanced cancer. most hematologic malignancies (hm) are incurable and typically follow unpredictable remitting-relapsing pathways associated with varying need for treatment, which may be distressing for patients. distress symptoms and psychological disorders secondary to cancer have also been shown to have significant negative consequences for both the patient and the family. maladaptive coping and abnormal illness behavior have been associated with psychiatric conditions, with negative effects on adherence to treatment, health behavior, and quality of life (grassi et al 2017). moreover, an increased length of stay in the hospital and/or an increased time in rehabilitation have been found to be more common among patients showing psychiatric symptoms, especially depression, than those with normal adjustment to illness (cordova et al 2017). unfortunately, cancer-related distress is commonly underrecognized and subsequently undertreated especially for patients with hm in developing countries. search in literature revealed several screening methods for the psychological consequences of cancer such as distress thermometer , symptom related checklist questionnaire, quality of life questionnaire, coping strategies questionnaire. also, guidelines for the management of psychological distress have been developed by several scientific cancer associations.

Eligibility criteria:
inclusion criteria: * a. inclusion criteria: 1. age will be more than or equal 18 years old regardless with six. 2. patients have been clinically diagnosed with haematological cancers. 3. being native egyptian patients. exclusion criteria: * history of psychiatric disorders. b) having other concomitant haematological diseases or solid neoplasm or relapse or other chronic disorders
ciprofol's impact on oxygenator function in extracorporeal membrane oxygenation (ecmo) patients

Conditions: ECMO Treatment; ARDS (Acute Respiratory Distress Syndrome); ECMO and Acute MI; Respiratory Failure Patients Treated With ECMO; Shock, Cardiogenic

Summary: this study evaluates the safety and effectiveness of ciprofol, a new sedative, in critically ill patients receiving extracorporeal membrane oxygenation (ecmo), a life-support system for heart or lung failure. the investigation aims to: assess how ciprofol affects the oxygenator, a critical ecmo component responsible for adding oxygen to blood. compare the safety of ciprofol to midazolam, a commonly used sedative. eligibility criteria adults aged 18 years or older. patients receiving ecmo and mechanical ventilation for over 72 hours. individuals requiring sedation for medical procedures. study protocol participants will be randomly assigned to one of two groups: ciprofol group: initial sedation dose of 0.1 mg/kg, adjusted as needed. midazolam group: initial sedation dose of 0.05 mg/kg, adjusted as needed. both groups will receive pain management with remifentanil. sedation levels will be adjusted daily by the clinical team to ensure patient safety and comfort. outcome measures primary: oxygenator performance (oxygen and carbon dioxide levels) on days 3 and 7. secondary: changes in blood triglyceride and clotting marker (d-dimer) levels, oxygenator lifespan before replacement, and safety outcomes such as low blood pressure, respiratory issues, or allergic reactions. significance ecmo patients often require prolonged sedation, but current sedatives like midazolam may contribute to oxygenator damage. ciprofol's potential for faster recovery and fewer side effects could improve sedation practices and device longevity in this high-risk population.


Eligibility criteria:
1. inclusion criteria: * receiving ecmo therapy with an anticipated duration exceeding 72 hours; * requiring invasive mechanical ventilation; * requiring sedation and analgesia treatment. 2. exclusion criteria: * bmi \>45 kg/m²; * age \<18 years; * severe hepatic (child-pugh class c) or renal failure (egfr \<15 ml/min/1.73m²); * history of severe psychiatric disorders; * pregnancy; * refusal to sign informed consent; * contraindications to midazolam and propofol use.

Keywords: ciprofol ecmo oxygenator function sedative randomized controlled trial midazolam oxygenator thrombosis
combined spinal-epidural versus spinal analgesia for elective caesarean section in the postoperative period

Conditions: Satisfaction; Pain

Summary: combined spinal epidural (csea) and single shot spinal anesthesia (sssa) are both well-established anesthetic methods for caesarean section. csea combines the advantages of spinal anesthesia for the surgery, and epidural anesthesia for postoperative pain management. the aim of this randomized trial was to compare analgesia and patient satisfaction with csea continuous epidural administration of local anesthetics versus sssa with oral pain medication in the postoperative period.

combined spinal epidural (csea) and single shot spinal anesthesia (sssa) are both well-established anesthetic methods for caesarean section. csea combines the advantages of spinal anesthesia for the surgery, and epidural anesthesia for postoperative pain management. however, it is more time-consuming, and adds potentially risks of both single techniques. the aim of this randomized trial was to compare analgesia and patient satisfaction with csea continuous epidural administration of local anesthetics versus sssa with oral pain medication in the postoperative period.

Eligibility criteria:
inclusion criteria: * american society of anesthesiologists-physical status: i or ii * elective caesarean section exclusion criteria: * age under eighteen * maternal systemic diseases * allergies against the drugs used * systemic infection or local infection in the puncture area * dysfunctional coagulation * coagulation-inhibiting drugs
comparison of free-breathing 3d quantitative perfusion in patients with minoca and minoca-mimics

Conditions: Myocardial Infarction With Non-Obstructive Coronary Artery; Myocarditis Acute; Takotsubo Cardiomyopathy; Spontaneous Coronary Artery Dissection; Non ST Elevation Myocardial Infarction

Summary: this clinical study examines patients presenting with acute myocardial infarction and no significant coronary artery disease on coronary angiography (minoca) and patients with minoca-mimics with advanced cmr. the present study aims to: * assess the microvascular function with a novel quantitative 3d myocardial perfusion imaging approach in the acute phase and post-convalescence * refine the role and diagnostic potential of advanced quantitative cmr imaging * assess the potential prognostic significance of microvascular dysfunction and epicardial adipose tissue on cardiovascular outcomes participants will undergo advanced cmr imaging in the acute setting (within 10 days after event) and post convalescence (after 3 months).

advanced cmr includes a novel free-breathing motion-informed locally low-rank quantitative 3d myocardial perfusion imaging. perfusion imaging will be compared with 3d late gadolinium enhancement (lge) imaging. a cine dixon sequence is performed for the assessment of epicardial adipose tissue (eat).

Eligibility criteria:
inclusion criteria: * acute presentation with signs/symptoms of acute coronary syndrome or myocarditis * elevated cardiac biomarkers * no signficant coronary artery disease on coronary angiogram or coronary ct exclusion criteria: * pacemaker/other devices or claustrophobia * severe asthma, chronic obstructive lung or kidney disease * acute pulmonary embolism * arrhythmia on ecg * moderate to severe valvular disease

Keywords: minoca minoca-mimics cmr 3d perfusion advanced cmr imaging
profitability trial in primary preventive implantable cardioverter-defibrillator recipients

Conditions: Ischaemic Cardiomyopathy; Non-ischaemic Cardiomyopathy

Summary: the purpose of this study is further risk stratification of patients receiving implantable cardioverter-defibrillator in primary prevention of sudden cardiac death.

current criteria for risk stratification of patients in risk of sudden cardiac death are mainly based on left ventricular ejection fraction and nyha class. this criteria are too robust, approximately 2/3 of icd recipients do not profit from this treatment in the following 5 years, especially those with non-ischaemic cardiomyopathy. we plan to sub-stratify this group of patients with both ischaemic and non-ischaemic cardiomyopathy by: non-linear heart rate variability analysis, microvolt t-wave alternans, qrt-t angle and character and amount of left ventricular scarring assessed by magnetic resonance imaging. pre-implantation values will be correlated with numbers and character of icd therapy (both anti-tachycardial pacing and icd discharge). the results may allow to decrease the number of patients, who do not profit from icd treatment.

Eligibility criteria:
inclusion criteria: * lvd (left ventricular dysfunction) d/t mi (myocardial infarction), lvef 30% or less, nyha (new york heart association class) ii, iii * lvd d/t mi, lvef 30% to 35%, nyha ii, iii * lvd d/t mi, lvef 30% to 40%, nsvt, positive ep study * lvd d/t mi, lvef 30% or less, nyha i * nicm (non-ischaemic cardiomyopathy), lvef 30% or less, nyha ii, iii * nicm, lvef 30% to 35%, nyha ii, iii * nicm, lvef 30% or less, nyha i * signed informed consent exclusion criteria: * metallic foreign body (metal sliver) in their eye, or who have an aneurysm clip in their brain, cannot have an mri scan since the magnetic field may dislodge the metal * severe claustrophobia may not be able to tolerate an mri scan * heart rhythm device in place before enrollment * atrial fibrillation in time of enrollment * icd implantation indicated from secondary prevention of scd (sudden cardiac death) * nyha or ccs class iv * pci or cabg in last 3 months * cmp/tia in last 3 months * syncope of unknown etiology

Keywords: icd (implantable cardioverter-defibrillator) heart rate variability mtwa (microvolt t-alternans) magnetic resonance imaging (mri)
efficacy and safety of bovine intestinal alkaline phosphatase (biap) during heart surgery

Conditions: Inflammation

Summary: this multi-centre prospective, randomised, double-blind, placebo-controlled study is designed to evaluate the efficacy and safety of bovine intestinal alkaline phosphatase (biap) in reducing the pro-inflammatory post-surgical responses and thereby preserving organ functions in patients undergoing invasive cardiac surgery: combined aortic valve replacement and coronary artery bypass grafting.


Eligibility criteria:
inclusion criteria: * male or non-pregnant, non-lactating female patients of any race in the ages of \>18 years. * patients scheduled for combined aortic valve replacement and cabg surgery. * patients who have given written informed consent prior to participation in the trial and who undertake to comply with the protocol. exclusion criteria: * patients who are unwilling or unable to be fully evaluated for follow-up. * patients who have base ap levels at \> 125 iu/l, or levels \< 30 iu/l (ammediol, dea (diethanolamine) units) * patients who show pre-operative infections or who are suspected of endocarditis or systemic infection. * patients who refuse to accept medically-indicated blood products. * patients who have evidence of significant hepatic disease, including history of clinical signs or laboratory values of total bilirubin \> 34.2 µmol/l (\> 2.0 mg/dl), alt (\>120) or ast (\>135) corresponding to \> 3x upper limit of normal. * patients who received investigational drugs in the 30 days prior to study drug administration, or are currently participating in a study during which the administration of investigational drugs within one month is anticipated. * patients who require pre-operative ventilatory support. * patients who have renal insufficiency (history of creatinine \>177mol/l or \>2.0 mg/dl) or chronic renal failure requiring dialysis. * patients who are planned to receive leukocyte-depletion filtration as part of the bypass circuitry. * patients with severe neurological deficits. * patients who have a recent history of drug or alcohol abuse. * patients with a diagnosis of idiopathic thrombocytopenia. * patients with a history of cancer who have received chemotherapy or radiation therapy within the past 3 months. patients receiving only adjuvant hormonal therapy are not excluded. * patients who are scheduled to receive "stress doses" of glucocorticoids (i.e., doses \>2 mg/kg/day of methylprednisolone or equivalent) prior to, during or following surgery. * patients who are vegetarians or veganists or those patients that may be expected not to be tolerant for bovine proteins. * patients who are, in the opinion of the investigator, unsuitable for the study. a well-documented screening log should be present in the clinic.

Keywords: valve replacement cabg sirts combined aortic valve replacement and cabg surgery
mirna in patients with thoracic, abdominal and intracranial aneurysms

Conditions: Vascular Aneurysm

Summary: to assess the expression of mirna in patients with taa, aaa in aneurysmatic tissue and to compare this expression with the healthy tissue in the same patient. in the same cohort, to asses the presence of mirna in plasma and to compare with the control group. over the period of three years,to follow subjects in order to assess if the presence of certain mirnas speeds up or slows down the progression of disease. in patients with intracranial aneurysms to detect mirna in plasma especially in patients with familial occurrence.

micrornas constitute a recently discovered class of non-coding rnas that play key roles in the regulation of gene expression. acting at the post-transcriptional level, micrornas have been shown to be involved in a wide range of biological processes such as cell cycle control, apoptosis and several developmental and physiological processes including stem cell differentiation, hematopoiesis, hypoxia, cardiac and skeletal muscle development. in addition to their important roles in healthy individuals, micrornas have also been implicated in a number of diseases including a broad range of cancers, cardiovascular and heart disease. their different expression in aortic tissue in patients with aortic abdominal aneurysm and their association with the progression of the disease were confirmed. they represent the potential target for the treatment of the disease. mirna act as biomarkers showing the potential risk of the presence of taa, aaa and intracranial aneurysm, for the prediction of taa and aaa progression and for the discovery of new treatment possibilities.

Eligibility criteria:
inclusion criteria: 1. 18 years of age or older 2. patient willing and able to sign clinical trial informed consent 3. patient with aaa or taa who require an open surgical procedure, or patient with intracranial aneurysm indicated for radiological intervention exclusion criteria: 1. patient with multiorgan failure

Keywords: mirna
study of the absorption, metabolism, and route of elimination of a novel class of anti-hiv 1 drugs (bms-955176) in humans.

Conditions: HIV Infections

Summary: the purpose of this study is to assess the pharmacokinetics (pk), metabolism, routes and extent of elimination, safety and tolerability of a single oral dose of \[14c\] bms-955176 in healthy male subjects. there is no formal research hypothesis to be statistically tested for this study.


Eligibility criteria:
inclusion criteria: * healthy male subjects * ages 18-50 years * body weight of at least 110 lbs (50kg) * bmi of 18 to 32 kg/m\^2 * non-smoking exclusion criteria: * clinically significant diagnostic or therapeutic radiation exposure within the previous 12 months (eg serial x-ray or cat scans, barium meals). * gastrointestinal disease including gastrointestinal surgery * constipation or irregular bowel movements
inflammatory response after muscle and skeleton trauma

Conditions: Multiple Trauma

Summary: the purpose of this study is to determine the inflammatory response after multiple trauma in humans.

polytraumatized patients are via a systemic inflammatory response syndrome at high risk for an uneventful outcome in the posttraumatic phase. one of the main functions of the inflammatory response is the recognition and elimination of damaged tissues and microorganisms. in polytraumatized patients, a huge amount of damaged cells occurs which has to be eliminated by programmed cell death (apoptosis)without damaging surrounding tissues. it remains unclear whether, when and how an interplay of complement system, nf-kb, danger and pattern recognition receptors, apoptosis, mesenchymal stem cells and their regulation may be beneficial and harmful. differing activation of the complement system, pro-inflammatory biomarkers and predisposing polymorphisms of response and receptor genes are expected to lead to varying outcome. therefore, this prospective observational study will enroll n=60 polytraumatized patients with an iss\>18 to monitor longitudinally their inflammatory response after trauma and to find out whether there is a discriminating pattern of the cross talk between complement system, biomarkers and apoptosis in patients with beneficial or harmful outcome.

Eligibility criteria:
inclusion criteria: * multiple trauma injury, injury severity score (iss) \> 18 with 1. isolated fractures of the extremities 2. fractures of the extremities combined with blunt/penetrating visceral trauma 3. fractures of the extremities combined with blunt/penetrating thoracic trauma 4. isolated head injury with morphological changes in cct 5. combination of points 1 - 4 exclusion criteria: * life expectancy \< 24 hours * participation in other trials * iss \< 18 * cardiopulmonary reanimation on the accident scene or dying immediately after hospital admission * age \< 18 years * known or suspected pregnancy * patients with ray-treatment or chemotherapy within the last three months

Keywords: humans patients polytrauma complement inflammation inflammatory response biomarkers cytokines cell surface markers apoptosis nf-kappab functional polymorphisms mesenchymal stem cell severity of injury iss infections systemic inflammatory response syndrome sirs sepsis severe sepsis shock organ dysfunctions sofa severity of disease apacheii sapsii spaps3 length of stay wound healing outcome mortality
acute effects of propylene glycol/glycerol intake on blood parameters

Conditions: Metabolic Complication

Summary: the aim of this study is to evaluate the acute effect of propylene glycol and glycerol intake on cardiorespiratory blood parameters.

background : propylene glycol/glycerol intake is increasingly popular. acute effect of propylene glycol and glycerol intake on cardiorespiratory blood parameters is unknown. the investigators postulate that intake of propylene glycol and glycerol could modifiy cardiorespiratory blood parameters. aims of this study : to test the following hypotheses : 1) acute intake of propylene glycol and glycerol modifies cardiorespiratory blood parameters. to test this hypothesis, we will perform blood samples before and after intake of propylene glycol and glycerol. participants will be tobacco smoker between 18 and 70 years old, with multiple cardiovascular risk factors, and who will undergo a cardiac catherization. after the cardiac catherization, the catheter will be used to perform serial blood samples.

Eligibility criteria:
inclusion criteria: * subject undergoing cardiac catherization * subject must be an active tobacco smoker exclusion criteria: * symptoms of infection or inflammation * acute disease including heart rhythm disorder, acute coronary syndrome or decompensation of a chronic disease (heart failure, copd,...) * unexpected and undesirable effects during the cardiac catherization procedure * respiratory failure requiring supplementary oxygen
myopia prevention through monitoring and motivating outdoor activities with smartwatches

Conditions: Myopia, Progressive

Summary: the goal of this multi-center, randomized, parallel-controlled clinical trial is to evaluate the effectiveness of outdoor activities monitoring and motivating by smartwatches to prevent myopia progression in children. the main question it aims to answer are: 1. to evaluate the two-year change of spherical equivalent progression. 2. to evaluate the change in axial length, the incidence of myopia, the time of outdoor activity, the choroid thickness, and blood flow through the two-year intervention. participants will wear smartwatches and receive mini program outdoor activity reminders and motivations. the required outdoor activity time is 2 hours from monday to friday and more than 2 hours on weekends. the control group will only wear smartwatches for monitoring. researchers will compare the control group and the intervention group to see if outdoor activities can protect myopia or not.


Eligibility criteria:
inclusion criteria: 1. gender is not limited; 2. age: 4 \~ 9 years old; 3. spherical equivalent: -0.5d \< se \< 2.5d; 4. be able to follow up for at least 2 years; 5. be able to wear a smartwatch on a daily basis as required; 6. parents or guardians sign an informed consent form; 7. children over 6 years old need oral consent to participate. exclusion criteria: 1. anisometropia \> 1.50d; 2. using other interventions for controlling myopia including atropine, rigid orthokeratology lenses, bifocal lenses or progressive lenses, red light, acupuncture, etc.; 3. strabismus and/or amblyopia; 4. previous history of eye surgery (including strabismus correction); 5. ocular or systemic diseases that may be related to the development of myopia or myopia: such as marfan syndrome, neonatal retinopathy, diabetes, etc.; 6. other circumstances that the investigator judges inappropriate to participate in the trial.
a clinical research study for the suppression and treatment of genital herpes infection in hiv-infected persons

Conditions: Herpes Genitalis

Summary: this clinical research study will be an international trial evaluating the safety and effectiveness of a marketed drug compared to placebo (like a sugar pill) for the suppression of repeated genital herpes infections in hiv-infected subjects with cd4+ count \<100 cells/mm3.


Eligibility criteria:
inclusion criteria: * cd4+ lymphocyte count \<100cells/mm3 at the screening visit. * documented history of hiv infections * must have received stable, combination anti hiv drugs for at least 4 months immediately prior to participation, and per the investigator, are unlikely to require change in anti-hiv drugs during the six-month study. * laboratory confirmation of genital herpes (a positive herpes simplex virus-2 antibody test). * 3 or more outbreaks of genital herpes in the previous 12 months if not on genital herpes medicines currently. * 3 or more outbreaks of genital herpes per year in the period prior to beginning of treatment for chronic genital herpes. exclusion criteria: * kidney diseases. * liver diseases. * known allergic reactions to valtrex (valaciclovir), zovirax (acyclovir), famvir (famciclovir), or cytovene (ganciclovir). * vomiting syndrome. * must be willing to discontinue taking current genital herpes medicines 1 week prior to participation. * active aids-indicator conditions, as defined by cdc category c. * other protocol inclusion and exclusion criteria to be evaluated by the research physician.

Keywords: herpes genital herpes hiv hsv